Stocks · News reference
Clearmind Medicine Completes Treatment For All Participants In Part A Of Its Ongoing Phase I/II Clinical Trial Evaluating CMND-100 For Alcohol Use Disorder
All 24 participants across cohorts 1 through 4 have successfully completed treatment according to the study protocol.The Company is currently assessing the dataset and, assuming results remain favorable, intends to
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jul 28, 2026, 11:49 AM
- Checked
- Jul 28, 2026, 11:49 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
SciSparc Unit Neurothera Labs And Clearmind Medicine Publish U.S. Patent Application For A Novel Combination Of 3,4-Methylenedioxymethamphetamine And N-Acylethanolamines For Use In Methods Of Treating Post-Traumatic Stress Disorder, Anxiety And Eating Disorders
Read original at benzingaClearmind Medicine Makes Clinical Progress in Alcohol Addiction Treatment Trial
Clearmind Medicine advances the CMND-100 clinical trial for alcohol use disorder to Parts B and C following positive Phase A safety data.
Read original at benzingaClearmind Medicine Says DSMB Unanimously Approved Advancing Phase 1/2 Trial Of CMND-100 To Parts B And C In Alcohol Use Disorder Patients And Healthy Participants
Read original at benzinga